Published in J Nucl Med on August 01, 1988
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2008) 1.72
The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur J Nucl Med Mol Imaging (2010) 1.62
Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol (2012) 1.24
Causes and imaging features of false positives and false negatives on F-PET/CT in oncologic imaging. Insights Imaging (2011) 1.23
Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer (2010) 1.11
18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res (2011) 1.03
Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer. Eur Radiol (2008) 1.02
Imaging response to systemic therapy for bone metastases. Eur Radiol (2009) 0.99
Bony metastases: assessing response to therapy with whole-body diffusion MRI. Cancer Imaging (2011) 0.97
Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer (2014) 0.81
Role of Imaging in Prostate Cancer. PET Clin (2009) 0.81
Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP. Indian J Clin Biochem (2013) 0.80
Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging (2007) 0.80
Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer (1997) 0.79
Alkaline phosphatase flare phenomenon following epidermal growth factor receptor-tyrosine kinase inhibitor treatment of non-small cell lung cancer: Report of a case and case review. Respir Med Case Rep (2014) 0.77
Diagnostic Role of (18)F-FECH-PET/CT Compared with Bone Scan in Evaluating the Prostate Cancer Patients Referring with Biochemical Recurrence. ISRN Oncol (2012) 0.76
A study of the relationship of metabolic MR parameters to estrogen dependence in breast cancer xenografts. NMR Biomed (2015) 0.76
The Super-scan and Flare Phenomena in a Nasopharyngeal Cancer Patient: A Case Report. J Clin Med Res (2012) 0.75
The flare phenomenon: still learning after 35 years. Eur J Nucl Med Mol Imaging (2011) 0.75
Prostate Cancer With Metastatic Lytic Bone Lesions: Positive Bone Scan Post Docetaxel Chemotherapy in the Setting of Clinically Successful Treatment. Urol Case Rep (2016) 0.75
The best of both worlds - managing the cancer, saving the bone. Nat Rev Endocrinol (2015) 0.75
Flare response versus disease progression in patients with non-small cell lung cancer. J Radiol Case Rep (2012) 0.75
Dual X-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients. Clin Exp Metastasis (2000) 0.75
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
The clinical course of bone metastases from breast cancer. Br J Cancer (1987) 4.93
Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet (1991) 4.09
Assessment of response to therapy in advanced breast cancer. Br J Cancer (1977) 3.70
Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28
Stress and relapse of breast cancer. BMJ (1989) 3.07
The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer (1999) 2.89
Association of alkaline phosphatase with an autoantigen recognised by circulating anti-neutrophil antibodies in systemic vasculitis. Lancet (1987) 2.85
Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations. Biochem J (1967) 2.78
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Standardization of clinical enzyme assays. J Clin Pathol (1971) 2.49
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Reconstitution of interleukin 2 with albumin for infusion. Lancet (1990) 2.37
Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer (1996) 2.28
Who needs steroid receptor assays? Lancet (1989) 2.27
Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet (1996) 2.23
Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg (1989) 2.23
Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer (1998) 2.20
Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol (1994) 2.11
Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc Natl Acad Sci U S A (1993) 2.10
Quality control in routine clinical chemistry. Adv Clin Chem (1967) 2.02
Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med (1996) 1.99
Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol (1998) 1.94
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol (1990) 1.94
Inhibition of the orthophosphatase and pyrophosphatase activities of human alkaline-phosphatase preparations. Biochem J (1967) 1.90
Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. BMJ (1988) 1.89
Changes in plasma -glutamyl transpeptidase activity associated with alterations in drug metabolism in man. Br Med J (1973) 1.76
Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol (1992) 1.74
Oestrogen receptors and the response to endocrine therapy in advanced breast cancer. Br J Cancer (1978) 1.71
Inadequacy of iridium implant as sole radiation treatment for operable breast cancer. Eur J Cancer (1996) 1.70
Serum -glytamyl transpeptidase activity in liver disease. Gut (1972) 1.69
Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer (1993) 1.68
Bone metastases and breast cancer. Cancer Treat Rev (1985) 1.67
Abbreviations for names of enzymes of diagnostic importance. J Clin Pathol (1971) 1.65
Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet (1983) 1.61
Alkaline phosphatase isoenzymes. Clin Chem (1982) 1.57
Bone densitometry: current status and future prospects. Br J Radiol (1997) 1.57
Periprosthetic bone remodelling of two types of uncemented femoral implant with proximal hydroxyapatite coating: a 3-year follow-up study addressing the influence of prosthesis design and preoperative bone density on periprosthetic bone loss. Osteoporos Int (2003) 1.56
Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: role of TNF-alpha and IL-1-beta. Immunology (1994) 1.55
Provisional recommendations on IFCC methods for the measurement of catalytic concentrations of enzymes. Part 2. IFCC method for aspartate aminotransferase. Clin Chim Acta (1976) 1.55
Transcatheter embolisation to control severe bleeding in fungating breast cancer. Eur J Surg Oncol (1988) 1.53
Prenatal diagnosis in Duchenne muscular dystrophy: Salvage of normal male fetus. Lancet (1978) 1.52
Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density. Am J Transplant (2006) 1.51
Contact quantitative ultrasound: an evaluation of precision, fracture discrimination, age-related bone loss and applicability of the WHO criteria. Osteoporos Int (1999) 1.51
Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med (2001) 1.49
1alpha-hydroxyvitamin D3 in primary hyperparathyroidism. Clin Endocrinol (Oxf) (1977) 1.48
Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation. Calcif Tissue Int (2010) 1.48
Advanced breast cancer: use of resources and cost implications. Br J Cancer (1993) 1.48
Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer (2003) 1.47
Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet (1984) 1.45
Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer (1993) 1.45
Action of neuraminidase on human kidney alkaline phosphatase. Nature (1966) 1.45
Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am (2006) 1.43
Activities of bone and liver alkaline phosphatases in serum in health and disease. Clin Chim Acta (1977) 1.43
Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol (1983) 1.42
Occupational dose to the radiographer in dual X-ray absorptiometry: a comparison of pencil-beam and fan-beam systems. Br J Radiol (1996) 1.41
Ablation of mediastinal parathyroid adenomas by superselective embolization of the internal mammary artery with alcohol. Clin Radiol (1993) 1.39
The role of nuclear medicine in orthopaedics. Nucl Med Commun (1994) 1.39
1, 2, 3, or 4 phase bone imaging--how many are necessary? Nucl Med Commun (1990) 1.39
Absorption of oral diphosphonate in normal subjects. Clin Endocrinol (Oxf) (1986) 1.38
Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer (1981) 1.36
Hypercalcaemia of malignancy: evidence for a nonparathyroid humoral agent with an effect on renal tubular handling of calcium. Clin Sci (Lond) (1984) 1.36
Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer (1994) 1.35
"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer (1991) 1.35
Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet (1983) 1.35
Retracted Recombinant migration inhibitory factor induces nitric oxide synthase in murine macrophages. J Immunol (1993) 1.31
A new combined approach to the conservative treatment of early breast cancer. Surgery (1984) 1.30
Visual assessment of vertebral deformity by X-ray absorptiometry: a highly predictive method to exclude vertebral deformity. Osteoporos Int (2000) 1.30
The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med (1978) 1.30
Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet (1986) 1.30
Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer (1990) 1.29
Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer (2000) 1.26
Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet (1985) 1.26
Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound? Osteoporos Int (2000) 1.25
Organic pyrophosphates as substrates for human alkaline phosphatases. Biochem J (1967) 1.25
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol (1990) 1.25
Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med (1999) 1.24
Mastectomy or conservation for early breast cancer: psychological morbidity. Eur J Cancer (1992) 1.22
Prognosis in inoperable stage III carcinoma of the breast. Eur J Cancer (1977) 1.22
Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors. Eur J Cancer (1993) 1.21
DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer (1990) 1.21
Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br J Cancer (1989) 1.21
A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer (1997) 1.20
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer (2003) 1.20
Chronic low back pain: comparison of bone SPECT with radiography and CT. Radiology (1992) 1.18
Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer (1988) 1.18
Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancet (1984) 1.18
A simplified heat-inactivation method for investigating alkaline phosphatase isoenzymes in serum. Clin Chim Acta (1975) 1.15
Histochemical studies with an estrogen receptor-related protein in human breast tumors. Cancer Res (1986) 1.15
Hypercalcaemia and metastatic bone disease: is there a causal link? Lancet (1982) 1.15
Analysis of heat inactivation curves of alkaline phosphatase isoenzymes in serum. Clin Chim Acta (1975) 1.15
A clinical profile of back pain and disability in patients with spinal osteoporosis. Bone (1994) 1.14
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer (1999) 1.14
Analysis of IL-2, IL-4, and IFN-gamma-producing cells in situ during immune responses to protein antigens. J Immunol (1993) 1.13
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol (1996) 1.13
Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer (1978) 1.13